Why the study?
Group B Coxsackieviruses cause severe multi-organ diseases including myocarditis, but there are no approved vaccines or effective treatments, requiring animal models to aid in understanding pathogenesis and therapy development.
This review summarizes the current state and future prospects of animal models for studying group B Coxsackievirus infections, which are crucial for developing vaccines and antiviral therapies.
Answers are grounded in this paper and cite their sources.
Optimized CVB animal models enable preclinical testing; leaves open human vaccine or therapy translation.
Group B Coxsackieviruses (CVBs) consist of six serotypes, CVB1 to CVB6, which can clinically affect the heart, brain, liver, pancreas and other organs, causing myocarditis, encephalitis, myelitis, pancreatitis, hand-foot-and-mouth disease (HFMD) and other diseases, and can even lead to death. CVBs are widespread globally and highly contagious. However, there are currently no approved CVB vaccines or effective treatments. The construction and optimization of animal models will aid in the in-depth understanding of CVB infections and its pathogenesis, providing essential tools for the exploration of vaccine development and antiviral therapies. This paper reviews the latest research progress and application prospects of CVB animal models.
No takes yet. Share an insight, caveat, or question.
Zhu et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: